Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large
prospective cohort study to identify current demographics and patterns of care of FL in the …

E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …

Clinical features and outcomes of FL patients in Chinese population are limited, thus
promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled …

The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL).
Recently, complete response at 30 months (CR 30) has been suggested as a surrogate for …

Background The benefit of adding rituximab to anthracycline-based therapy for follicular
lymphoma grade 3 has not been studied. Patients and methods We retrospectively reviewed …

Defining the role of high-dose therapy with autologous stem cell rescue in the therapeutic
algorithm of follicular lymphoma remains a major challenge. In contrast to the acknowledged …

Follicular lymphoma (FL) exhibits striking biologic and clinical heterogeneity. Patients with
newly diagnosed asymptomatic or low-bulk disease may be observed or managed with …

Follicular lymphomas are characterized by relatively long median survivals and a
continuous pattern of relapse. The heterogeneity in these diseases is increasingly …

Single-center experiences have shown that intensified treatments with autologous
transplantation are a promising therapeutic strategy for patients with high-risk follicle-center …

Abstract Abstract 97 Background: There is no consensus or standard of care for front-line
therapy for FL as demonstrated by our initial publication of the National LymphoCare Study …